GENPHARMASEC LIMITED (GENPHARMA.BO)
INR 3.42
(0.89%)
INR 3.42
(0.89%)
| Breakdown | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -24.72 Million | -32.11 Million | -22.77 Million | -18.08 Million | 19.41 Million | -60.52 Million |
| Net Income | -1.25 Million | 11.24 Million | -2.09 Million | 12.57 Million | 10.09 Million | 2.3 Million |
| Depreciation & Amortization | 421 Thousand | 197 Thousand | 142 Thousand | 124.67 Thousand | 49.18 Thousand | 2484.00 |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | -35.4 Million | -37.68 Million | -18.28 Million | -29.78 Million | 7.79 Million | -62.47 Million |
| Other non-cash items | 27.84 Million | 33.5 Million | 18 Million | 30.63 Million | -1.66 Million | 52.42 Million |
| Investing Cash Flow | -285.35 Million | 5.15 Million | 3.51 Million | -17.36 Million | -45.63 Million | -107.76 Million |
| Investments in PPE | -184 Thousand | -160 Thousand | -805 Thousand | -124.65 Thousand | -524.38 Thousand | - |
| Acquisitions | 184 Thousand | - | 17 Thousand | - | - | - |
| Investment purchases | -176.39 Million | - | - | -129.67 Million | -41.5 Million | -140.59 Million |
| Sales/Maturities of investments | - | 3.32 Million | 2.73 Million | 67.35 Million | 23.3 Million | 59.36 Million |
| Other Investing Activities | -108.78 Million | 1.98 Million | 1.57 Million | 45.07 Million | -26.91 Million | -26.53 Million |
| Financing Cash Flow | 478.47 Million | 30.82 Million | - | 45 Million | - | 218.72 Million |
| Debt repayment | -1.84 Million | -30.82 Million | - | - | - | -9.88 Million |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | 277.4 Million | - | - | 45 Million | - | 228.6 Million |
| Other Financing Activities | 206.65 Million | - | - | - | - | - |
| Accounts receivables | -33.9 Million | 7.38 Million | 10.76 Million | -4.91 Million | -69.97 Million | -359.78 Thousand |
| Accounts payables | 10.08 Million | -48.5 Million | -8.94 Million | 15.74 Million | 55.32 Million | 72.79 Thousand |
| Inventory | 8.33 Million | 2.13 Million | -22.08 Million | -42.2 Million | 17.89 Million | -52.5 Million |
| Other working capital | -19.92 Million | 1.29 Million | 1.97 Million | 1.59 Million | 4.53 Million | -9.68 Million |
| Cash at beginning of period | 19.93 Million | 16.06 Million | 35.33 Million | 25.78 Million | 51.99 Million | 1.56 Million |
| Cash at end of period | 31.69 Million | 19.93 Million | 16.06 Million | 35.33 Million | 25.78 Million | 51.99 Million |
| Capital Expenditure | -184 Thousand | -160 Thousand | -805 Thousand | -124.65 Thousand | -524.38 Thousand | - |
| Effect of forex changes on cash | - | -1.00 | - | - | - | - |
| Net cash flow / Change in cash | 11.76 Million | 3.86 Million | -19.26 Million | 9.55 Million | -26.21 Million | 50.43 Million |
| Free Cash Flow | -24.91 Million | -32.27 Million | -23.58 Million | -18.2 Million | 18.89 Million | -60.52 Million |
| Breakdown | 2023 FY | 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 FY | 2022 Q4 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -1.25 Million | 634 Thousand | 79 Thousand | 261 Thousand | 11.24 Million | 10.45 Million |
| Depreciation & Amortization | 421 Thousand | 47 Thousand | 8000.00 | 70 Thousand | 197 Thousand | 60 Thousand |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | -35.4 Million | - | - | - | -37.68 Million | - |
| Other non-cash items | 27.84 Million | -587 Thousand | -8000.00 | -70 Thousand | 33.5 Million | -60 Thousand |
| Investing Cash Flow | -285.35 Million | - | - | - | 5.15 Million | - |
| Investments in PPE | -184 Thousand | - | - | - | -160 Thousand | - |
| Acquisitions | 184 Thousand | - | - | - | - | - |
| Investment purchases | -176.39 Million | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | 3.32 Million | - |
| Other Investing Activities | -108.78 Million | - | - | - | 1.98 Million | - |
| Financing Cash Flow | 478.47 Million | - | - | - | 30.82 Million | - |
| Debt repayment | -1.84 Million | - | - | - | -30.82 Million | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | 277.4 Million | - | - | - | - | - |
| Other Financing Activities | 206.65 Million | - | - | - | - | - |
| Accounts receivables | -33.9 Million | - | - | - | 7.38 Million | - |
| Accounts payables | 10.08 Million | - | - | - | -48.5 Million | - |
| Inventory | 8.33 Million | - | - | - | 2.13 Million | - |
| Other working capital | -19.92 Million | - | - | - | 1.29 Million | - |
| Cash at beginning of period | 19.93 Million | 11.44 Million | 11.36 Million | 19.93 Million | 16.06 Million | 9.47 Million |
| Cash at end of period | 31.69 Million | 11.53 Million | 11.44 Million | 261 Thousand | 19.93 Million | 19.93 Million |
| Capital Expenditure | -184 Thousand | - | - | - | -160 Thousand | - |
| Effect of forex changes on cash | - | - | - | - | -1.00 | - |
| Net cash flow / Change in cash | 11.76 Million | 94 Thousand | 79 Thousand | -19.67 Million | 3.86 Million | 10.45 Million |
| Free Cash Flow | -24.91 Million | 94 Thousand | 79 Thousand | 261 Thousand | -32.27 Million | 10.45 Million |
GATE
SPOI
SLSDF
HBIE
032350
DIABIO